Uniqure NV (NASDAQ:QURE) Director Philip Astley-Sparke sold 5,000 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $30.39, for a total value of $151,950.00. Following the completion of the transaction, the director now directly owns 23,252 shares in the company, valued at approximately $706,628.28. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
QURE traded down $0.69 during mid-day trading on Thursday, hitting $28.93. 27,116 shares of the stock were exchanged, compared to its average volume of 596,626. Uniqure NV has a 1-year low of $14.68 and a 1-year high of $43.23. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -9.84 and a beta of 0.81.
Uniqure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.03. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%. The firm had revenue of $3.15 million for the quarter, compared to analyst estimates of $3.37 million. On average, research analysts forecast that Uniqure NV will post -2.57 earnings per share for the current year.
Several equities analysts recently issued reports on the company. HC Wainwright increased their target price on Uniqure from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, September 24th. Cantor Fitzgerald set a $58.00 target price on Uniqure and gave the stock a “buy” rating in a research note on Thursday, August 23rd. BidaskClub lowered Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 28th. Cowen reissued a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Uniqure in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $55.67.
Hedge funds have recently bought and sold shares of the business. Gagnon Securities LLC acquired a new stake in Uniqure in the 2nd quarter valued at about $209,000. Trexquant Investment LP acquired a new stake in Uniqure in the 2nd quarter valued at about $272,000. Oppenheimer & Co. Inc. acquired a new stake in Uniqure in the 3rd quarter valued at about $279,000. BlueMountain Capital Management LLC acquired a new stake in Uniqure in the 2nd quarter valued at about $383,000. Finally, CIBC World Markets Inc. acquired a new stake in Uniqure in the 2nd quarter valued at about $392,000. 60.62% of the stock is currently owned by institutional investors.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Read More: Institutional Investors
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.